Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center

Transplant International

Volumn 22, Issue 12, 2009, Pages 1140-1150

  Kofler, Sieglinde ^a   Bigdeli, Amir K ^a   Kaczmarek, Ingo ^a   Kellerer, Diana ^a   Müller, Thomas ^b   Schmoeckel, Michael ^a   Steinbeck, Gerhard ^a   Überfuhr, Peter ^a   Reichart, Bruno ^a   Meiser, Bruno ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute rejection; Chronic allograft vasculopathy; Heart transplantation; Immunosuppression; Survival

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PROSTANOID; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOMYOPATHY; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEART PRESERVATION; HEART TRANSPLANTATION; HEART TUMOR; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NITRIC OXIDE; ORGAN PRESERVATION SOLUTIONS; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 70449121816     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00931.x     Document Type: Article

References (33)

1. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official report - 2001. J Heart Lung Transplant 2001 20 : 805.
2. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997 64 : 1120.
3. Kaczmarek I, Sadoni S, Schmoeckel M, et al. The need for a tailored immunosuppression in older heart transplant recipients. J Heart Lung Transplant 2005 24 : 1965.
4. Lower RR, Shumway NE. Studies on the orthotopic homotransplantations of the canine heart. Surg Forum 1960 11 : 18.
5. Human PA, Holl J, Vosloo S, et al. Extended cardiopulmonary preservation: University of Wisconsin solution versus Bretschneider's cardioplegic solution. Ann Thorac Surg 1993 55 : 1123.
6. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999 18 : 143.
7. Groetzner J, Kaczmarek I, Landwehr P, et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004 25 : 333.
8. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 2001 72 : 638.
9. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996 124 : 820.
10. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003 107 : 93.
11. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001 20 : 611.
12. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967 41 : 1271.
13. Grimm M, Rinaldi M, Yonan NA, Arpesella G. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006 6 : 1387.
14. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998 66 : 507.
15. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993 56 : 75.
16. Kirklin JK, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994 13 : 444.
17. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993 25 : 754.
18. Kaczmarek I, Ertl B, Schmauss D, et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006 25 : 550.
19. Reichenspurner H, Russ C, Meiser BM. University of Wisconsin solution for myocardial protection in heart transplantation - a comparison with HTK. Transplant Proc. 1993 25 : 3042.
20. Kajihara N, Morita S. The UW solution has greater potential for longer preservation periods than the Celsior solution: comparative study for ventricular and coronary endothelial function after 24-h heart preservation. Eur J Cardiothorac Surg 2006 29 : 748.
21. Michel P, Vial R. A comparative study of the most widely used solutions for cardiac graft preservation during hypothermia. J Heart Lung Transplant 2002 21 : 1030.
22. Taylor DO, Edwards LB. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report - 2007. J Heart Lung Transplant 2007 26 : 769.
23. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005 15 : 272.
24. Kobashigawa JA, Miller LW, Russell SD. Tacrolismus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006 6 : 1377.
25. Petrakopoulou P, Anthopoulou L, Muscholl M, et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J Am Coll Cardiol 2006 47 : 1622.
26. Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008 6 : 229.
27. Kaczmarek I, Deutsch MA, Rohrer ME, et al. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies? J Heart Lung Transplant 2006 25 : 1057.
28. Grande AM, Gaeta R, Campana C, et al. Comparison of standard and bicaval approach in orthotopic heart transplantation: 10-year follow-up. J Cardiovasc Med 2008 9 : 493.
29. Weiss ES, Nwakanma LU, Russell SB, Conte JV, Shah AS. Outcomes in bicaval versus biatrial techniques in heart transplantation: an analysis of the UNOS database. J Heart Lung Transplant 2008 27 : 178.
30. Raghavan C, Maloney JD, Nitta J, et al. Long-term follow-up of heart transplant recipients requiring permanent pacemakers. J Heart Lung Transplant 1995 14 : 1081.
31. Luebbert JJ, Lee FA, Rosenfeld LE. Pacemaker therapy for early and late sinus node dysfunction in orthotopic heart transplant recipients: a single-center experience. Pacing Clin Electrophysiol 2008 31 : 1108.
32. Russo MJ, Davies RR, Hong KN, et al. Matching high-risk recipients with marginal donor hearts is a clinically effective strategy. Ann Thorac Surg 2009 87 : 1066.
33. Wittwer T, Wahlers T. Marginal donor grafts in heart transplantation: lessons learned from 25 years of experience. Transpl Int 2008 21 : 113.